Suppr超能文献

80 岁及以上女性的乳腺癌:一个被低估实体的综合分析。

Breast cancer in women 80 years of age and older: a comprehensive analysis of an underreported entity.

机构信息

University Hospital Basel (UHB), Breast Center, Basel, Switzerland.

出版信息

Acta Oncol. 2013 Jan;52(1):57-65. doi: 10.3109/0284186X.2012.731523. Epub 2012 Oct 22.

Abstract

BACKGROUND

Approximately 10% of breast cancer (BC) patients are over the age of 80. We present the first comprehensive review on this particular group of patients.

PATIENTS AND METHODS

The treatments and disease courses of an unselected cohort of patients, whose age at first diagnosis was ≥ 80 years (n = 151), were compared to those of a group of women, who were aged 56-66 years (n = 372).

RESULTS

The group of elderly patients had larger tumors at first diagnosis (25 mm vs. 18 mm, p < 0.001) and higher disease stages (I: 31.1% vs. 44.1%, IV: 11.9% vs. 5.4%; each p < 0.001). There were no significant differences between both groups in terms of histologic subtype, grading, hormonal receptor status and HER2 status. The tumors of older patients were more often detected by clinical examination (38.9% vs. 17.0%, p < 0.001) and less often by mammography/sonography (10.4% vs. 29.9%, p < 0.001). The rate of patients who died of BC were similar in both groups (21.2% vs. 21.5%, p = 1.00). In the patients who had no evidence of metastases and who opted for primary non-surgical management (n = 21), the tumor could be stabilized without considerable morbidity in only 42.9%. Persistence to adjuvant endocrine therapy was comparable (83.0% vs. 88.3%, p = 0.357). In the adjuvant as well as in the palliative settings, elderly patients received less chemotherapy than younger ones (adjuvant: 1.6% vs. 23.3%; palliative: 32.3% vs. 68.4%; each p < 0.001). For palliative treatments only, elderly patients received fewer treatment regimens (≥ 3 therapy lines: 16.0% vs. 54.9%, p < 0.001). In those patients who died of BC, elderly women had inferior overall (25 vs. 54.5 months, p < 0.001) as well as metastatic-disease survival (11.5 vs. 19 months, p = 0.062).

CONCLUSION

It must be ensured that appropriate standard therapies should not be routinely withheld in older patients based on erroneous perceptions regarding the biological nature of BC in the elderly and lack of knowledge about available therapy regimens. Physicians should consider that preservation of current life circumstances and maintenance of quality of life are frequently more important than "classical" hard medical facts such as survival times.

摘要

背景

约 10%的乳腺癌(BC)患者年龄在 80 岁以上。我们首次对这组特殊患者进行了全面综述。

患者和方法

对一组未经选择的患者(年龄≥80 岁,n=151)的治疗和疾病过程进行了评估,并与年龄在 56-66 岁的一组女性(n=372)进行了比较。

结果

老年患者首次诊断时肿瘤更大(25mm 比 18mm,p<0.001),疾病分期更高(I 期:31.1%比 44.1%,IV 期:11.9%比 5.4%;均 p<0.001)。两组之间在组织学亚型、分级、激素受体状态和 HER2 状态方面没有显著差异。老年患者的肿瘤更多地通过临床检查(38.9%比 17.0%,p<0.001)而不是通过乳房 X 线摄影/超声检查(10.4%比 29.9%,p<0.001)发现。两组死于 BC 的患者比例相似(21.2%比 21.5%,p=1.00)。在没有转移证据且选择非手术治疗的原发性疾病患者中(n=21),只有 42.9%的患者能够稳定肿瘤而不会产生显著的发病率。辅助内分泌治疗的持续性相似(83.0%比 88.3%,p=0.357)。在辅助治疗和姑息治疗中,老年患者接受的化疗少于年轻患者(辅助治疗:1.6%比 23.3%;姑息治疗:32.3%比 68.4%;均 p<0.001)。仅姑息治疗中,老年患者接受的治疗方案更少(≥3 个治疗线:16.0%比 54.9%,p<0.001)。在死于 BC 的患者中,老年女性的总生存期(25 比 54.5 个月,p<0.001)和转移性疾病生存期(11.5 比 19 个月,p=0.062)均较差。

结论

不能基于对老年患者 BC 生物学特性的错误认识以及对现有治疗方案的缺乏了解,常规拒绝为老年患者提供适当的标准治疗。医生应考虑到维持当前的生活环境和生活质量通常比“经典”硬医学事实(如生存时间)更重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验